Browsing: GLP1

This is a paid press release. Contact the press release distributor directly with any enquiries.

Novo NordiskNVO and Eli LillyLLY lead the diabetes and obesity market, driven by their blockbuster GLP-1 therapies. Lilly sells its dual GIP/GLP-1 agonist tirzepatide as Mounjaro for type II diabetes and as Zepbound for obesity. Novo Nordisk markets semaglutide as Ozempic and Rybelsus for type II diabetes, and as Wegovy for weight management

The GLP-1 and active nutrition category, in particular, can be further segmented into three sub-groups: products for GLP-1 users, GLP-1 adjacent products, and products for post-GLP-1 users

July 20, 2026 – Adolescents and young adults in the U.S. are increasingly using popular GLP-1 weight-loss drugs alone or in conjunction with metabolic and bariatric surgery (MBS) to manage obesity, according to a study by UT Southwestern Medical Center researchers published in JAMA Pediatrics

GLP-1 medications have garnered global interest for their benefits in weight loss and diabetes management. Growing consumer access to these products is driving innovations in the food and nutrition industries for healthier, nutrient-dense options in smaller portion sizes. 

Anthony Colón, RN Releases Free Educational Guide to Help Adults Evaluate GLP-1 Telehealth Providers New reuestions about provider qualifications, patient safety, and ongoing medical care

My brother-in-law is a lovely man, but for years he’s suffered from obesity. He also gambles and drinks alcohol too much. I hesitate to get too involved, but I recently read that the new weight-loss drugs based on GLP-1 agonists are also helpful in reducing alcohol and gambling addictions. This sounds too good to be…

Vt. (WCAX) – The UVM Health Network is dropping insurance coverage for GLP-1 weight-loss drugs, a move that could affect hundreds of employees and save the cash-strapped health network nearly $19 million

A Wendell woman’s experience with self-injected GLP-1 medication landed her in the hospital for three days and left her with a $9,000 medical bill

Va. (WDBJ) – The use of GLP-1 weight-loss drugs has grown, and so has the amount Americans are paying for them. A Northwestern University study found that average payments for the medications by people without diabetes jumped 157% between 2017 and 2022. The study’s authors said employers and insurers are paying more for the medications,…